|
|
|
Publicacions |
 |
Benito Menni CASM ha publicat nombrosos articles i llibres especialitzats, a més
de l’edició periòdica de la revista Informaciones Psiquiátricas
que podeu consultar a la web:
http://www.revistahospitalarias.org
A continuació posem a la vostra disposició la relació de les
publicacions recents.
Treballs publicats en revistes internacionals 2005-2006:
[1] Salvador R, Martinez A, Pomarol-Clotet E, Sarro S, Fletcher P, Bullmore ET. Frequency based mutual information measures between clusters
of brain regions in functional magnetic resonance imaging. Neuroimage
(2007), doi:101016/jneuroimage200612001. 2007.
[2] Amann BL, Mergl R, Vieta E, Born C, Hermisson I, Seemueller F, et al.
A 2-Year, Open-Label Pilot Study of Adjunctive Chromium in Patients With Treatment-Resistant
Rapid-Cycling Bipolar Disorder. J Clin Psychopharmacol. 2007 Feb;27(1):104-6.
[3] Sterr A, Padberg F, Amann B, Mergl R, Mulert C, Juckel G, et al.
Electroencephalographic abnormalities associated with antidepressant treatment:
a comparison of mirtazapine, venlafaxine, citalopram, reboxetine, and amitriptyline.
J Clin Psychiatry. 2006 Feb;67(2):325-6.
[4] Sterr A, Amann B, Grunze H. [Prophylaxis of bipolar
disorder]. Psychiatr Prax. 2006 Mar;33 Suppl 1:S47-54.
[5] Sarró S, Dueñas RM, Galve L, Mediavilla R, Mensa I, Sole J, et al.
Validación de la escala de Calgary en pacientes con esquizofrenia crónica.
Informaciones psiquiátricas. 2006;182(4):203-13.
[6] Pomarol-Clotet E, Honey GD, Murray GK, Corlett PR, Absalom AR, Lee M, et al.
Psychological effects of ketamine in healthy volunteers.
Phenomenological study. Br J Psychiatry. 2006 Aug;189:173-9.
[7] Parthasarathi UD, Harrower T, Tempest M, Hodges JR, Walsh C, McKenna PJ, et
al. Psychiatric presentation of voltage-gated potassium
channel antibody-associated encephalopathy. Case report. Br J Psychiatry.
2006 Aug;189:182-3.
[8] Menon M, Pomarol-Clotet E, McKenna PJ, McCarthy R.
Probabilistic reasoning in schizophrenia: A comparison of the performance of deluded
and nondeluded schizophrenic patients and exploration of posible ognitive underpinnings.
Cognitive Neuropsychiatry. 2006;11 (6):521-36.
[9] McKenna PJ. What works in schizophrenia: cognitive
behaviour therapy is not effective. BMJ. 2006 Aug 12;333(7563):353.
[10] Leeson VC, Laws KR, McKenna PJ. Formal thought disorder
is characterised by impaired lexical access. Schizophr Res. 2006 Dec;88(1-3):161-8.
[11] Honey GD, O'Loughlin C, Turner DC, Pomarol-Clotet E, Corlett PR, Fletcher PC.
The effects of a subpsychotic dose of ketamine on recognition
and source memory for agency: implications for pharmacological modelling of core
symptoms of schizophrenia. Neuropsychopharmacology. 2006 Feb;31(2):413-23.
[12] Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, et al.
Clozapine alone versus clozapine and risperidone with refractory schizophrenia.
N Engl J Med. 2006 Feb 2;354(5):472-82.
[13] Corlett PR, Honey GD, Aitken MR, Dickinson A, Shanks DR, Absalom AR, et al.
Frontal responses during learning predict vulnerability
to the psychotogenic effects of ketamine: linking cognition, brain activity, and
psychosis. Arch Gen Psychiatry. 2006 Jun;63(6):611-21.
[14] Amann B, Sterr A, Vieta E, Stampfer R, Walden J, Grunze H.
An exploratory open trial on safety and efficacy of the anticonvulsant retigabine
in acute manic patients. J Clin Psychopharmacol. 2006 Oct;26(5):534-6.
[15] Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms
of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced
weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet
Genomics. 2005 Apr;15(4):195-200.
[16] San L, Arranz B, Escobar R. Pharmacological management
of acutely agitated schizophrenic patients. Curr Pharm Des. 2005;11(19):2471-7.
[17] Ros S, Aguera L, de la Gandara J, Rojo JE, de Pedro JM.
Potentiation strategies for treatment-resistant depression. Acta Psychiatr
Scand Suppl. 2005(428):14-24, 36.
[18] Rojo JE, Ros S, Aguera L, de la Gandara J, de Pedro JM.
Combined antidepressants: clinical experience. Acta Psychiatr Scand Suppl.
2005(428):25-31, 6.
[19] Rojo JE, Gibert K, Cobo J, Rodriguez-Cano E, Vallejo J.
Onset of antidepressant action: a pharmacological question? Hum Psychopharmacol.
2005 Aug;20(6):425-33.
[20] Orth M, Amann B, Robertson MM, Rothwell JC. Excitability
of motor cortex inhibitory circuits in Tourette syndrome before and after single
dose nicotine. Brain. 2005 Jun;128(Pt 6):1292-300.
[21] Orth M, Amann B, Ratnaraj N, Patsalos PN, Rothwell JC.
Caffeine has no effect on measures of cortical excitability. Clin Neurophysiol.
2005 Feb;116(2):308-14.
[22] Menon M, Woodward TS, Pomarol-Clotet E, McKenna PJ, McCarthy R.
Heightened stimulus salience renders deluded schizophrenics less susceptible to
the 'famous names illusion'. Schizophr Res. 2005 Dec 15;80(2-3):369-71.
[23] Leeson VC, Simpson A, McKenna PJ, Laws KR. Executive
inhibition and semantic association in schizophrenia. Schizophr Res.
2005 Apr 1;74(1):61-7.
[24] Leeson VC, McKenna PJ, Murray G, Kondel TK, Laws KR.
What happens to semantic memory when formal thought disorder remits? Revisiting
a case study. Cognit Neuropsychiatry. 2005 Jan;10(1):57-71.
[25] Leeson VC, McKenna PJ, Laws KR. Storage and access
procedures in schizophrenia: evidence for a two phase model of lexical impairment.
J Clin Exp Neuropsychol. 2005 Aug;27(6):700-10.
[26] Honey GD, Pomarol-Clotet E, Corlett PR, Honey RA, McKenna PJ, Bullmore ET,
et al. Functional dysconnectivity in schizophrenia associated
with attentional modulation of motor function. Brain. 2005 Nov;128(Pt
11):2597-611.
[27] Honey GD, Honey RA, Sharar SR, Turner DC, Pomarol-Clotet E, Kumaran D, et al.
Impairment of specific episodic memory processes by sub-psychotic
doses of ketamine: the effects of levels of processing at encoding and of the subsequent
retrieval task. Psychopharmacology (Berl). 2005 Sep;181(3):445-57.
[28] Gajwani P, Forsthoff A, Muzina D, Amann B, Gao K, Elhaj O, et al.
Antiepileptic drugs in mood-disordered patients. Epilepsia. 2005;46 Suppl
4:38-44.
[29] Dibben CR, Kalavalapalli SS, Linnington HE, Hynes FA, Dinneen SF, Adler AI,
et al. Diabetes associated with atypical antipsychotic
treatment may be severe but reversible: case report. Int J Psychiatry
Med. 2005;35(3):307-11.
[30] de la Gandara J, Rojo JE, Ros S, Aguera L, de Pedro JM.
Neuropharmacological basis of combining antidepressants. Acta Psychiatr
Scand Suppl. 2005(428):11-3, 36.
[31] de la Gandara J, Aguera L, Rojo JE, Ros S, de Pedro JM.
Use of antidepressant combinations: which, when and why? Results of a Spanish survey.
Acta Psychiatr Scand Suppl. 2005(428):32-6.
[32] de la Gandara J, Aguera L, Rojo JE, Ros S. Working
group on combined antidepressants (G.E.A.A.: grupo para el estudio de las asociaciones
de antidepresivos). Acta Psychiatr Scand Suppl. 2005(428):5-6.
[33] Barrera A, McKenna PJ, Berrios GE. Formal thought
disorder in schizophrenia: an executive or a semantic deficit? Psychol
Med. 2005 Jan;35(1):121-32.
[34] Amann B, Sterr A, Mergl R, Dittmann S, Seemuller F, Dobmeier M, et al. Zotepine loading in acute and severely manic patients: a
pilot study. Bipolar Disord. 2005 Oct;7(5):471-6.
[35] Amann B, Grunze H. Neurochemical underpinnings in
bipolar disorder and epilepsy. Epilepsia. 2005;46 Suppl 4:26-30.
[36] Aguera LF, Rojo JE, Ros S, de la Gandara J, de Pedro JM.
Antidepressant combinations: epidemiological considerations. Acta Psychiatr
Scand Suppl. 2005(428):7-10, 36.
Llibres
[1] McKenna PJ. Schizophrenia and related syndromes.
2nd ed. Hove ; New York: Taylor & Francis 2007.
[2] McKenna PJ, Oh TM. Schizophrenic speech : making sense
of bathroots and ponds that fall in doorways.
Cambridge ; New York: Cambridge University Press 2005.
[3] McKenna PJ. Schizophrenia and related syndromes.
Oxford ; New York: Oxford University Press 1994.
|
|